Navigation Links
Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers

HELSINKI, Finland, May 29, 2012 /PRNewswire/ --

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study.

"We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses," comments the Principal Investigator of the study, Chief Physician of Docrates Hospital, Dr. Timo Joensuu. "We believe that oncolytic adenoviruses, a generally well tolerated therapy, will have an important role in the future of cancer treatments."

"In our earlier experimental use the treatment has appeared to be safe for cancer patients. We really look forward to establishing the same safety in a clinical study with a more advanced dosing schedule. We believe the schedule used in the trial will also eventually contribute to the efficacy of the therapy," adds Helsinki University's Research Professor Akseli Hemminki, co-inventor of CGTG-102 and co-founder of Oncos Therapeutics.

The patient data cumulated over the past 5 years have contributed significantly to the design of the entire clinical development program of the company. "In addition to existing clinical safety data, which is unique to this stage of development, we also have a wealth of supportive data to guide the selection of target tumor types, optimal treatment administration, and other essential elements including clues regarding mechanism of action and possible biomarkers. We are very excited about the design of our entire development program driven by clinical data," summarizes Chief Medical Officer and Head of Research of Oncos Therapeutics, Mikael von Euler.

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit

SOURCE Oncos Therapeutics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software ... , The new Q-Suite 6 platform is based on the latest Java Enterprise standards. ... specific piece of software for many key components of the suite. Much of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is jam-packed ... the palates of attendees is of the utmost importance. Whether you are cooking ... give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the ... several models of traditional and far-infrared saunas. , For traditional saunas, Finnleo ... most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White ...
Breaking Medicine News(10 mins):